NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TVRD

Tvardi Therapeutics Inc

Jun 20 • 04:00PM ET

25.77

Dollar change +0.18
Percentage change 0.70	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD VRTX BPMC ARWR SRPT AVXL AMRN NKTR LGND OPK

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-29.62	Insider Own	32.22%	Shs Outstand	9.36M	Perf Week	-1.30%
Market Cap	241.23M	Forward P/E	-	EPS next Y	-3.49	Insider Trans	-0.04%	Shs Float	6.34M	Perf Month	-7.10%
Enterprise Value	252.83M	PEG	-	EPS next Q	-0.73	Inst Own	2.26%	Short Float	2.57%	Perf Quarter	64.24%
Income	-45.08M	P/S	31.87	EPS this Y	-108.63%	Inst Trans	1.54%	Short Ratio	4.46	Perf Half Y	173.22%
Sales	7.57M	P/B	-	EPS next Y	-9.46%	ROA	-69.86%	Short Interest	0.16M	Perf YTD	40.36%
Book/sh	-5.30	P/C	7.05	EPS next 5Y	-	ROE	-414.88%	52W Range	8.13 - 34.31	Perf Year	104.52%
Cash/sh	3.66	P/FCF	-	EPS past 3/5Y	9.46% 12.29%	ROIC	-119.42%	52W High	-24.89%	Perf 3Y	-90.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-32.33% -18.53%	Gross Margin	94.89%	52W Low	217.16%	Perf 5Y	-95.24%
Dividend TTM	-	EV/Sales	33.40	EPS Y/Y TTM	63.53%	Oper. Margin	-408.16%	Volatility	0.72% 7.10%	Perf 10Y	-92.85%
Dividend Ex-Date	-	Quick Ratio	31.73	Sales Y/Y TTM	-55.30%	Profit Margin	-595.39%	RSI (14)	49.08	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	32.48	EPS Q/Q	84.10%	SMA20	-6.18%	Beta	0.24	Target Price	56.20
Payout	-	Debt/Eq	-	Sales Q/Q	20.33%	SMA50	5.51%	Rel Volume	11.26	Prev Close	25.59
Employees	10	LT Debt/Eq	-	Earnings	May 13 AMC	SMA200	65.07%	Avg Volume	36.54K	Price	25.77
IPO	Jan 31, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	-450.43% -	Trades		Volume	411,634	Change	0.70%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-12-25	Initiated	Piper Sandler	Overweight	$78
May-21-25	Initiated	Oppenheimer	Outperform	$65
May-15-25	Initiated	BTIG Research	Buy	$55
Jun-13-24	Downgrade	Stifel	Buy → Hold	$6 → $1
Jun-13-24	Downgrade	Needham	Buy → Hold
Jun-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-13-24	Downgrade	Canaccord Genuity	Buy → Hold	$10 → $1
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $6
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight	$17 → $20
Nov-01-21	Resumed	Canaccord Genuity	Buy	$33
Aug-03-21	Initiated	JP Morgan	Neutral	$16
Apr-21-20	Reiterated	H.C. Wainwright	Buy	$30 → $33
Aug-12-19	Reiterated	H.C. Wainwright	Buy	$31 → $30
May-29-19	Reiterated	Laidlaw	Buy	$26 → $32
Feb-06-19	Resumed	Jefferies	Buy	$22
Jan-15-19	Initiated	BofA/Merrill	Neutral	$19
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy	$30
Aug-08-18	Reiterated	Stifel	Buy	$22 → $26
Jun-28-18	Reiterated	H.C. Wainwright	Buy	$24 → $26

Show Previous Ratings

Jun-01-25 06:05AM	Oppenheimer Predicts Up to ~550% Jump for These 2 Strong Buy Stocks (TipRanks)
May-27-25 08:00AM	Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis (Business Wire) +14.78%
May-20-25 08:00AM	Tvardi Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +5.88%
May-13-25 04:05PM	Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update (Business Wire)
May-06-25 07:00AM	Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference (Business Wire) -5.54%
11:50AM	Loading…
Apr-14-25 11:50AM	Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics (GlobeNewswire) +13.26%
Dec-27-24 07:00AM	Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split (GlobeNewswire) -15.98%
Dec-18-24 07:00AM	Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement (GlobeNewswire)
06:45AM	Tessera gets sickle cell funding; Corvus shares slide on eczema data (BioPharma Dive)
Nov-14-24 07:31PM	Cara: Q3 Earnings Snapshot (Associated Press Finance) -5.04%
Aug-15-24 01:55PM	Cara: Q2 Earnings Snapshot (Associated Press Finance)
Jul-11-24 07:00AM	Cara Therapeutics Announces Exploration of Strategic Alternatives (GlobeNewswire) +27.97%
Jun-13-24 09:51AM	Chipotle, McDonald's initiated: Wall Street's top analyst calls (The Fly) -34.72%
Jun-12-24 04:01PM	Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica (GlobeNewswire)
May-13-24 08:55PM	CARA Stock Earnings: Cara Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Loading…
05:10PM	Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:07PM	Cara: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 07:00AM	Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
Apr-02-24 07:00AM	Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-07-24 07:00AM	Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 (GlobeNewswire) +6.05%
06:40AM	7 F-Rated Stocks to Sell in March 2024 (InvestorPlace)
Mar-05-24 09:07AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.98%
07:51AM	Q4 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 08:51PM	CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +5.24%
05:10PM	Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Cara: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-12-24 04:01PM	Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 (GlobeNewswire) -8.54%
Jan-22-24 10:19AM	Cara Layoffs 2024: What to Know About the Latest CARA Job Cuts (InvestorPlace)
07:00AM	Loading…
07:00AM	Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026 (GlobeNewswire)
Dec-18-23 07:00AM	Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis (GlobeNewswire) -48.85%
Nov-14-23 11:04AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.20%
08:48AM	Q3 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-23 06:00PM	Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +12.38%
04:15PM	Cara: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-09-23 11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga) -6.72%
Nov-06-23 10:00AM	Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline (Zacks)
Nov-02-23 07:00AM	Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty (GlobeNewswire)
Oct-23-23 07:00AM	Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire)
Sep-25-23 07:00AM	Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients (GlobeNewswire)
Sep-05-23 07:00AM	Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.00%
Aug-10-23 02:53AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 05:54AM	Q2 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:15PM	Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.75%
04:09PM	Cara: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 07:00AM	Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors (GlobeNewswire)
Aug-02-23 07:00AM	Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-24-23 07:00AM	Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire)
Jun-14-23 01:37PM	The past five years for Cara Therapeutics (NASDAQ:CARA) investors has not been profitable (Simply Wall St.)
Jun-13-23 06:30AM	3 Small-Cap Stocks to Sell in June Before They Crash and Burn (InvestorPlace)
Jun-02-23 06:46PM	Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Jun-01-23 07:00AM	Cara Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 06:34PM	7 Stocks With 1,000% Upside Potential (InvestorPlace) -7.56%
May-25-23 06:40AM	Cara Therapeutics, Inc.'s (NASDAQ:CARA) P/S Is On The Mark (Simply Wall St.) -6.55%
May-18-23 04:53PM	Hero or Zero? 7 Speculative Small-Cap Stocks to Make You Rich or Broke. (InvestorPlace) -8.22%
02:00AM	Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus (PR Newswire)
May-16-23 11:02AM	Q1 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.23%
May-15-23 05:15PM	Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cara: Q1 Earnings Snapshot (AP Finance)
04:01PM	Cara Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 09:38AM	Cara Therapeutics, Inc. (NASDAQ:CARA) is a favorite amongst institutional investors who own 65% (Simply Wall St.)
May-01-23 07:00AM	Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire)
Apr-26-23 08:00PM	CARA: What does Argus have to say about CARA? (Argus Research)
Apr-10-23 07:00AM	Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-07-23 08:41AM	We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate (Simply Wall St.)
Mar-14-23 07:00AM	Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report (GlobeNewswire)
Mar-11-23 07:19AM	Things Look Grim For Cara Therapeutics, Inc. (NASDAQ:CARA) After Today's Downgrade (Simply Wall St.)
Mar-08-23 06:59AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 10:46AM	Metas stock up on report of more layoffs, and WeightWatchers telehealth deal gives it access to promising obesity drug market (MarketWatch) -33.23%
10:02AM	Q4 2022 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:43AM	Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss (Yahoo Finance Video)
08:05AM	Meta shares rise after new wave of layoffs, WeightWatchers stock makes gains after results and acquisition; Grindrs stock falls after profit drop (MarketWatch)
Mar-06-23 07:39PM	These 2 Stocks Are Plunging After Hours Monday (Motley Fool)
05:15PM	Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 10:00AM	Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-21-23 07:00AM	Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 (GlobeNewswire)
Feb-15-23 05:11AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
Feb-08-23 05:00PM	Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine (GlobeNewswire)
Jan-17-23 07:00AM	Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023 (GlobeNewswire)
Jan-03-23 07:00AM	Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-22 05:53AM	Cara Therapeutics (NASDAQ:CARA shareholders incur further losses as stock declines 8.8% this week, taking three-year losses to 35% (Simply Wall St.) +8.61%
Nov-29-22 07:30AM	KemPharm Announces Appointment of Christopher Posner as New Independent Director (GlobeNewswire)
Nov-09-22 06:08AM	Cara Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-07-22 05:35PM	Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Cara Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 08:46AM	Why Cara Therapeutics (CARA) Might Surprise This Earnings Season (Zacks)
Nov-03-22 07:00AM	Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors (GlobeNewswire)
Nov-02-22 10:01AM	Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out for (Zacks) -5.80%
07:00AM	Cara Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-22 10:00AM	Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-30-22 08:51AM	Cara Therapeutics, Inc. (NASDAQ:CARA) is a favorite amongst institutional investors who own 67% (Simply Wall St.)
Oct-24-22 07:00AM	Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022 (GlobeNewswire)
Oct-18-22 09:55AM	Wall Street Analysts See a 133% Upside in Cara (CARA): Can the Stock Really Move This High? (Zacks)
Oct-10-22 04:05PM	SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics (PR Newswire)
Sep-28-22 07:00AM	Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan (GlobeNewswire)
Sep-20-22 09:47AM	Here's Why We're Not Too Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Situation (Simply Wall St.)

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Posner Christopher	PRESIDENT AND CEO	Feb 28 '25	Sale	4.75	583	2,769	13,109	Mar 04 04:59 PM
Terrillion Scott	SEC'Y; CHIEF COMPLIANCE & G.C.	Feb 28 '25	Sale	4.76	163	776	7,190	Mar 04 04:58 PM
Posner Christopher	PRESIDENT AND CEO	Feb 04 '25	Sale	4.72	372	1,756	13,692	Feb 06 07:15 PM
Posner Christopher	PRESIDENT AND CEO	Nov 04 '24	Sale	0.29	3,668	1,064	168,768	Nov 06 04:51 PM
Posner Christopher	PRESIDENT AND CEO	Aug 01 '24	Sale	0.35	4,149	1,452	172,436	Aug 02 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVRD

Tvardi Therapeutics Inc

Upgrade your FINVIZ experience